By Fineline Cube Shanghai Henlius Biotech Inc. (HKG: 2696) announced the dosing of the first patient in China for its global Phase I clinical study (HLX15-SC-NDMM-001) evaluating HLX15-SC, a subcutaneous formulation of its self-developed daratumumab biosimilar, as a first-line treatment for newly diagnosed multiple myeloma (NDMM).
Development Program Overview
| Parameter | Detail |
|---|---|
| Company | Shanghai Henlius Biotech Inc. (HKG: 2696) |
| Study Identifier | HLX15-SC-NDMM-001 |
| Study Phase | Global Phase I |
| Indication | Newly diagnosed multiple myeloma (NDMM) – first-line treatment |
| Molecule | HLX15-SC (subcutaneous daratumumab biosimilar) |
| Reference Products | Darzalex (IV) and Darzalex Faspro (SC) – Johnson & Johnson |
| Regulatory Status | IND approved by U.S. FDA for multiple myeloma indication |
Product Profile & Innovation
- Molecular Structure: Fully human anti-CD38 IgG1κ monoclonal antibody
- Development Status: Independently developed biosimilar candidate to J&J’s daratumumab products
- Formulation Advantage: Subcutaneous delivery offers improved convenience over intravenous administration
- Market Opportunity: First-in-class biosimilar opportunity in major markets where no daratumumab biosimilar has yet been approved
- Competitive Landscape: Targets $7+ billion global daratumumab franchise with dual formulation strategy (HLX15 IV and HLX15-SC)
Regulatory & Market Context
- Unmet Biosimilar Need: No daratumumab biosimilar currently approved in United States, Europe, or Japan
- FDA Milestone: Investigational New Drug (IND) application previously received approval from U.S. FDA for multiple myeloma indication
- Global Strategy: China-first patient dosing represents initial step in comprehensive international development program
- Commercial Potential: Multiple myeloma affects approximately 160,000 new patients annually worldwide, with daratumumab-based regimens becoming standard of care
Strategic Significance for Henlius
- Portfolio Expansion: Represents Henlius’ entry into the high-value hematologic oncology biosimilar space
- Platform Validation: Demonstrates company’s capability to develop complex monoclonal antibody biosimilars with alternative formulations
- International Ambitions: FDA IND approval signals regulatory pathway viability in world’s largest pharmaceutical market
- Competitive Differentiation: Subcutaneous formulation addresses growing preference for patient-friendly administration routes
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development timelines, regulatory approvals, and market expectations for HLX15-SC. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and market access challenges.-Fineline Info & Tech